Gilead's Kite Files US Application To Expand Use Of Yescarta In Second-Line Setting

  • Kite Pharma, a Gilead Science Inc Company GILD, has submitted a supplemental marketing application to the FDA for Yescarta (axicabtagene ciloleucel).
  • The application seeks to expand Yescarta's current indication to include adults with relapsed or refractory large B-cell lymphoma (LBCL) in the second-line setting.
  • The filing is based on data from the ZUMA-7 study with a follow-up of over two years. 
  • The study met the primary endpoint of event-free survival (EFS; hazard ratio 0.398), representing a clinically meaningful 60% reduction in risk of EFS events versus standard of care. 
  • The interim analysis of overall survival (OS) showed a trend favoring Yescarta; however, the data are immature at this time, and further analyses are planned for the future.
  • Detailed results from ZUMA-7 have been submitted for presentation at an upcoming medical congress. 
  • Related content: Benzinga's Full FDA Calendar.
  • Yescarta is a CD19-directed genetically modified autologous T cell immunotherapy indicated for relapsed or refractory LBCL after two or more lines of systemic therapy.
  • Price Action: GILD stock traded 1.50% lower at $68.80 premarket on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralBriefslymphoma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!